GlassScriptPhysician profile
Samer Alsamman
NPI 1669720835
$7,350.00
in general payments reported to CMS, 2019-2025
18 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $17.96 · 2021: $14.50 · 2022: $428 · 2023: $629 · 2024: $4,736 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $2,481 · Travel and Lodging: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $2,481.00 |
| Travel and Lodging | $1,488.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,005.92 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $1,069.90 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $882.26 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $477.96 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $300.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $144.90 | 2022-2024 | Uptravi, Opsumit |
| Penumbra, INC. | $122.31 | 2023 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.88 | 2020-2025 | Stiolto Respimat |
| Electromed, INC. | $53.42 | 2022-2025 | Smartvest |
| Grifols USA, LLC | $42.64 | 2023-2025 | Prolastin-C Liquid |
| Insmed, INC. | $41.80 | 2024-2025 | Arikayce |
| Inogen, INC. | $26.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.09 | 2025 | Glassia |
| Viatris Specialty LLC | $22.17 | 2025 | Yupelri |
| Verona Pharma, INC. | $20.71 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.14 | 2023 | Dupixent |
| Amgen INC. | $15.72 | 2025 | Tezspire |
| Ethicon INC. | $14.98 | 2025 | Monarch Platform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Alsamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.